catalyst calendar
/
← Catalyst calendar

IBRX biotech catalysts & pipeline

IMMUNITYBIO INC · Data as of 2026-10-25

Upcoming catalysts

nogapendekin alfa inbakicept-pmln (ANKTIVA) — FDA meeting

2026

Discussions planned with the U.S. FDA in 2026 for the accelerated approval pathway
Source filing

nogapendekin alfa inbakicept-pmln (ANKTIVA) — NDA/BLA submission

Q4 2026

ImmunityBio anticipates reporting topline results in November 2026 and remains on track to submit an sBLA to the FDA in the fourth quarter of 2026 for ANKTIVA plus BCG in patients with BCG-naïve NMIBC.
Source filing

nogapendekin alfa inbakicept-pmln (ANKTIVA) — Topline data

Nov 2026

ImmunityBio anticipates reporting topline results in November 2026 and remains on track to submit an sBLA to the FDA in the fourth quarter of 2026 for ANKTIVA plus BCG in patients with BCG-naïve NMIBC.
Source filing

Explore the free biotech catalyst calendar